{"prompt": "['SAR439774 (formerly ALN-AT3SC) (fitusiran)', 'Clinical Study Protocol ALN-AT3SC-004', '(Sanofi Genzyme EFC14769)', '27 Jun 2018', '11.', 'APPENDICES', '11.1.', 'Pharmacokinetic Assessment Time Points', 'Table 7 provides a schedule for the collection of blood samples for PK analysis in all fitusiran', 'arm patients.', 'Table 7: Pharmacokinetic Time Points for All Fitusiran Arm Patients', 'Study Day', 'Protocol Time (hh:mm)', 'PK Blood', 'Predose', 'X', '(within 240 minutes before dosing)', 'Day 1', '04:00 (=30 min)', 'X', 'Predose', 'Day 29 (7 days)', 'X', '(within 240 minutes before dosing)', 'Predose', 'Day 85 (=7 days)', 'X', '(within 240 minutes before dosing)', 'Predose', 'X', '(within 240 minutes before dosing) a', 'Day 197 (7 days)', '04:00 (=30 min)', 'X', 'Predose', 'Day 225 (=7 days)', 'X', '(within 240 minutes before dosing) a', 'a Time point used in population PK analysis.', 'Table 8 provides a schedule for the collection of blood samples for PK (fitusiran arm), AT, and', 'thrombin generation analysis in East Asian patients at East Asian sites.', 'Property of the Sanofi Group - strictly confidential', '76', '(electronic 1.0)']['SAR439774 (formerly ALN-AT3SC) (fitusiran)', 'Clinical Study Protocol ALN-AT3SC-004', '(Sanofi Genzyme EFC14769)', '27 Jun 2018', 'Table 8:', 'Pharmacokinetic (Fitusiran Arm), AT, and TG Time Points for East Asian Patients at', 'East Asian Sites', 'Protocol Time', 'Study Day', 'PK Blood', 'AT', 'TG', '(hh:mm)', 'Predose (within 240 minutes before', 'X', 'dosing)', '00:30 (=5 min)', 'X', '01:00 (=5 min)', 'X', 'Day 1', '02:00 (15 min)', 'X', '04:00 (=30 min) a', 'X', '06:00 (=30 min)', 'X', '08:00 (=30 min)', 'X', '12:00 (=30 min)', 'X', 'Day 2', '24:00 (=2 hours)', 'X', 'X', 'X', 'Day 8', '168 h', 'X', 'X', 'Predose (within 240 minutes before', 'Day 29 (7 days)', 'X', 'dosing)', 'Predose (within 240 minutes before', 'Day 85 (7 days)', 'X', 'dosing)', 'Predose (within 240 minutes before', 'X', 'Day 197 (7 days)', 'dosing)', '04:00 (=30 min)', 'X', 'Predose (within 240 minutes before', 'Day 225 (7 days)', 'X', 'dosing)', 'Abbreviations: AT=antithrombin; h=hours; min=minutes; PK=pharmacokinetics; TG=thrombin generation', 'a', 'Time point used in population PK analysis.', 'Table 9 provides a schedule for the collection of pooled urine samples for PK analysis in East', 'Asian patients in the fitusiran arm at East Asian sites. Volume must be recorded.', 'Table 9: Urine Pharmacokinetic Time Points for East Asian Patients in the Fitusiran Arm', 'from East Asian sites', 'Protocol Time', 'Study Day', '(hh:mm), Pooled Urine', 'Postdose (0:00) to 06:00 (=30 min)', 'Day 1', '06:00 (=30 min) to 12:00 (=30 min)', 'Day 2', '12:00 (=30 min) to 24:00 (=2 hours)', 'Property of the Sanofi Group - strictly confidential', '77', '(electronic 1.0)']['SAR439774 (formerly ALN-AT3SC) (fitusiran)', 'Clinical Study Protocol ALN-AT3SC-004', '(Sanofi Genzyme EFC14769)', '27 Jun 2018', '11.2.', 'Perioperative Schedule of Assessments', '11.2.1.', 'Definitions of Minor and Major Surgery', 'Minor surgery is defined as any invasive operative procedure in which only skin, mucous', 'membranes, or superficial connective tissue is manipulated and does not meet the criteria for', 'major surgery (eg, dental extraction of <3 non-molar teeth). Minor surgical procedures may be', 'performed at a local health care provider institution.', 'Major surgery is defined as any invasive operative procedure that requires any of the following:', 'Opening into a major body cavity (eg, abdomen, thorax, skull)', 'Operation on a joint', 'Removal of an organ', 'Dental extraction of any molar teeth or >3 non-molar teeth', 'Operative alteration of normal anatomy', 'Crossing of a mesenchymal barrier (eg, pleura, peritoneum, dura)', 'It is recommended that any elective non-dental major surgery be performed at a clinical study', 'center, when possible.', '11.2.2.', 'Perioperative Assessments of Safety and Hemostatic Efficacy in Patients', 'Undergoing Operative Procedures', 'In patients undergoing operative procedures during the treatment period, safety and hemostatic', 'efficacy assessments will be performed according to the Perioperative Schedule of Assessments', '(described below and outlined in Table 10), where possible.', 'After a review of medical and surgery history has been completed, patients will have the', 'following assessed as specified in the Perioperative Schedule of Assessments (Table 10):', 'directed physical examination and assessment of vital sign measurements; clinical laboratory', 'assessments including hematology (complete blood count, white blood count, red blood cell', 'count, hemoglobin, hematocrit, platelets); coagulation (APTT, PT/INR, fibrinogen, D-dimer);', 'hepatic assessments; and hemostatic efficacy assessments (rating scale based on ISTH Scientific', 'and Standardization Committee [SSC] definitions). [10]', 'Property of the Sanofi Group - strictly confidential', '78', '(electronic 1.0)']\n\n###\n\n", "completion": "END"}